Protagonist Therapeutics, Inc.
7707 Gateway Boulevard
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. Its primary focus is on developing first-in-class oral peptide drugs that specifically target biological pathways also targeted by currently marketed injectable antibody drugs. Compared to injectable antibody drugs, Protagonist's oral peptides offer targeted delivery to the gastrointestinal (GI) tissue compartment, potential for improved safety due to minimal exposure in the blood, improved convenience and compliance due to oral delivery, lower cost, and an opportunity for earlier introduction of targeted therapy for inflammatory bowel disease (IBD). Protagonist's initial lead product candidates, PTG-100 and PTG-200, are based on this approach, and the company believes they have the potential to transform the existing treatment paradigm for IBD, a GI disease consisting primarily of ulcerative colitis and Crohn's disease.
Founder: Mark Symythe
CEO: Dinesh Patel
CMO (Marketing): Richard Shames
CFO: Tom O’Neil
CSO (Scientific): David Liu
Please click here for Protagonist Therapeutics job opportunities.
Please click here for clinical trial information.
183 articles with Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today reported its financial results for the third quarter ended September 30, 2021 and provided a corporate update.
Protagonist Therapeutics Earns $7.5 Million Milestone Payment from IL-23 Receptor Collaboration with Janssen
Protagonist Therapeutics, Inc. today announced that it will receive a $7.5 million milestone payment from Janssen Biotech, Inc. (Janssen) triggered by the completion of the clinical data collection-related Phase 1 activities for PN-235 (JNJ-2113).
Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel , Ph.D., President and Chief Executive Officer and Scott Plevy , M.D., Executive Vice President and Therapeutic Head, Gastroenterology will participate in a fireside chat at the upcoming Jefferies Next Generation IB Therapeutics Summit taking place virtually on October 19, 2021.
Protagonist Therapeutics Announces Removal of FDA Clinical Hold on the Rusfertide Clinical Development Program
All ongoing clinical trials of rusfertide to resume dosing Phase 3 registrational trial planned to commence in the first quarter of 2022 Conference call scheduled for today at 8:00 A.M. ET
Protagonist Therapeutics announced Monday morning that the FDA had removed the hold on PV drug candidate rusfertide, clearing the way for all trials to resume.
Protagonist Therapeutics Announces Data from Phase 2 Rusfertide Study in Hereditary Hemochromatosis Selected for Oral Presentation at the Annual AASLD Meeting
Protagonist Therapeutics, Inc. announced that an abstract highlighting new results from its Phase 2 study of rusfertide in hereditary hemochromatosis has been selected for oral presentation at The Liver Meeting® 2021, hosted by the American Association for the Study of Liver Diseases, taking place virtually November 12-15, 2021.
The company announced Friday that clinical studies have been placed on hold following the development of tumors in mice in a non-clinical study.
Protagonist Therapeutics, Inc. announced the receipt of a verbal communication from the U.S. Food and Drug Administration that Protagonist's clinical studies for rusfertide, an investigational product candidate currently in development, have been placed on a clinical hold.
Protagonist Therapeutics, Inc. reported that on September 15, 2021, it issued inducement awards to two recently hired employees in accordance with the terms of their employment offer letters.
Protagonist Therapeutics Appoints Scott Plevy, M.D., Executive Vice President and Therapeutic Head, Gastroenterology
Protagonist Therapeutics, Inc. announced the appointment of Scott Plevy, M.D., to the role of Executive Vice President and Therapeutic Head, Gastroenterology.
Protagonist Therapeutics, Inc. today announced it has resolved its Collaboration Agreement dispute with Zealand Pharma by reducing future development and sales milestone payments and royalties owed to Zealand for Protagonist's product candidate rusfertide under the companies' 2012 Collaboration Agreement.
Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today reported its financial results for the second quarter ended June 30, 2021, and an overview of recent company progress.
Protagonist Therapeutics Announces Amendment of Agreement with Janssen Biotech for the Continued Development and Commercialization of IL-23 Antagonists
Protagonist Therapeutics, Inc. (Nasdaq:PTGX) ("Protagonist" or "the Company") today announced its entry into an amended collaboration agreement (the "Restated Agreement") with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, relating to research, development, manufacture and commercialization of multiple oral Interleukin (IL)-23 receptor antagonist drug candidates.
Protagonist Therapeutics, Inc. reported that on June 30, 2021, it issued an inducement award to Patrick Smith, the Company's recently hired Vice President, Quality Assurance, in accordance with the terms of Mr. Smith's employment offer letter.
Protagonist Therapeutics, Inc. Announces Closing of $132.2 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Protagonist Therapeutics, Inc. , today announced the closing of its previously announced underwritten public offering of 3,503,311 shares of its common stock.
The FDA granted it to Lu-PSMA-617, an investigational radioligand therapy to treat metastatic castration-resistant prostate cancer.
Protagonist Therapeutics, Inc. (Nasdaq: PTGX), a clinical stage biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 3,046,358 shares of its common stock at a price to the public of $37.75 per share.
Protagonist Therapeutics, Inc. (Nasdaq:PTGX), a clinical stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of $100,000,000 of shares of its common stock
Protagonist Therapeutics Announces Updated Phase 2 Data Supporting Long-Term Efficacy of Rusfertide in Polycythemia Vera
Protagonist Therapeutics announced updated results from the ongoing Phase 2 study of rusfertide, an investigational new drug being evaluated for the treatment of polycythemia vera.
Protagonist Therapeutics to Host Investor Conference Call and Webcast to Discuss Updated Phase 2 Rusfertide Results in Polycythemia Vera as Presented at EHA 2021
Protagonist Therapeutics announced that management will host an investor conference call and webcast to provide a brief corporate update and discuss data from its ongoing Phase 2 clinical study evaluating rusfertide in polycythemia vera, which was selected as an oral presentation at the European Hematology Association 2021 Annual Congress.